|
Age, y
|
|
18–25
|
–
| | | |
|
26–35
|
−8.4 (− 12.4; − 4.5)
|
< 0.001
|
−5.5 (− 9.5; − 1.4)
|
0.008+
|
|
36–45
|
− 14.6 (− 19.3; − 9.9)
|
< 0.001
|
− 9.7 (− 14.6; − 4.7)
|
< 0.001+
|
|
> 45
|
−22.6 (− 28.7; − 16.5)
|
< 0.001
|
− 15.4 (− 22.1; − 8.7)
|
< 0.001+
|
|
Sex, Female
|
1.7 (− 1.9; 5.2)
|
0.36
|
–
|
–
|
|
Baseline characteristics
|
|
Body mass index, kg/m2
|
−0.2 (− 0.9; 0.4)
|
0.66
|
–
|
–
|
|
Fat mass index, kg/m2
|
−0.3 (− 1.2; 0.5)
|
0.46
| |
–
|
|
Fat free mass index, kg/m2
|
−0.2 (− 1.2; 0.8)
|
0.72
|
–
|
–
|
|
Hypertension, Yes
|
0.01 (− 6; 6)
|
0.99
|
–
|
–
|
|
C-reactive protein, mg/L
|
−0.01 (− 0.1; 0.07)
|
0.99
|
–
|
–
|
|
CD4 count, cells/ul
|
0.002 (−0.01; 0.02)
|
0.83
|
–
|
–
|
|
On tuberculosis treatment, Yes
|
−1.8 (− 7.5; 3.9)
|
0.53
|
–
|
–
|
|
Hepatitis B surface antigen positive, Yes
|
4.2 (− 5.3; 13.8)
|
0.38
|
–
|
–
|
|
Hepatitis C virus antibody Positive, Yes
|
0.5 (−26.2; 27.3)
|
0.97
|
–
|
–
|
|
Viral load, log (copies+ 1/mL)
|
0.3 (−1.4; 2.1)
|
0.68
|
–
|
–
|
|
eGFR, ml/min/1.73 m2
|
0.3 (0.23; 0.38)
|
< 0.001
|
0.2 (0.1; 0.3)
|
< 0.001+
|
|
Six month change
|
|
Change in body mass index, kg/m2
|
0.1 (−1; 1.2)
|
0.87
|
–
|
–
|
|
Change in fat mass index, kg/m2
|
−0.4 (−1.8; 1)
|
0.58
|
–
|
–
|
|
Change in fat free mass index, kg/m2
|
0.8 (−1; 2.6)
|
0.37
|
–
|
–
|
|
Change in CD4 count, cells/ul
|
0.03 (0.01; 0.05)
|
< 0.001
|
0.01 (−0.005; 0.02)
|
0.18+
|
|
Viral load > 1000 copies/ml at 6 months, Yes
|
−15.1 (−23.4; −6.8)
|
< 0.001
|
−9.9 (− 17.2; − 2.5)
|
0.009+
|
|
Antiretroviral treatment
|
|
TDF Treatment
|
−2.5 (−7; 2)
|
0.28
|
0.2 (−3.8; 4.2)
|
0.93*
|
